Blood pressure control in hispanics in the antihypertensive and lipid-lowering treatment to prevent heart attack trial

Hypertension

Volumn 50, Issue 5, 2007, Pages 854-861

  Margolis, Karen L ^a   Piller, Linda B ^b   Ford, Charles E ^b   Henriquez, Mario A ^c   Cushman, William C ^d   Einhorn, Paula T ^e   Colon Sr , Pedro J ^f   Vidt, Donald G ^g   Christian, Rudell ^h   Wong, Nathan D ⁱ   Wright Jr , Jackson T ^j   Goff Jr , David C ^k  

^a HEALTHPARTNERS RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c Bronx Nephrology Hypertension   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^f Centro Cardiovascular de Puerto Rico y del Caribe   (Puerto Rico)

^g LERNER RESEARCH INSTITUTE   (United States)

^h NitroMed   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j CASE WESTERN RESERVE UNIVERSITY   (United States)

^k WAKE FOREST SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Blood pressure control; Clinical trials; Ethnicity; Hispanic; Hypertension; Race

Indexed keywords

AMLODIPINE; ATENOLOL; CHLORTALIDONE; CLONIDINE; DOXAZOSIN; HYDRALAZINE; LISINOPRIL; RESERPINE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE TITRATION; ETHNICITY; FEMALE; FOLLOW UP; HEALTH CARE ACCESS; HEALTH CARE COST; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; BLOOD PRESSURE; CANADA; CAUCASIAN; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HEART DISEASE; HISPANIC; HYPERTENSION; MIDDLE AGED; MULTICENTER STUDY; NEGRO; PUERTO RICO; STATISTICS; TREATMENT OUTCOME; UNITED STATES; VIRGIN ISLANDS (U.S.);

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; ATENOLOL; BLOOD PRESSURE; CANADA; CHLORTHALIDONE; CLONIDINE; DOUBLE-BLIND METHOD; DOXAZOSIN; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEART DISEASES; HISPANIC AMERICANS; HUMANS; HYDRALAZINE; HYPERTENSION; LISINOPRIL; MALE; MIDDLE AGED; PUERTO RICO; RESERPINE; TREATMENT OUTCOME; UNITED STATES; VIRGIN ISLANDS OF THE UNITED STATES;

EID: 35848954511     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.092650     Document Type: Article

References (39)

1. Ong KL, Cheung BMY, Man YB, Lau CP, Lam KSL. Prevalence, awareness, treatment and control of hypertension among United States adults 1999-2004. Hypertens. 2007;49:69-75.
2. Burt VL, Cutler JA, Higgins M, Horan MJ, Labarthe D, Whelton P, Brown C, Roccella EJ. Trends in prevalence, awareness, treatment, and control of hypertension in the adult US population. Hypertens. 1995;26:60-69.
3. Centers for Disease Control and Prevention. Hypertension among Mexican Americans - United States, 1982-1984 and 1988-1991. MMWR Morbid Mortal Wkly Rep. 1995;44:635-639.
4. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003;290:199-206.
5. Centers for Disease Control and Prevention. Racial/ethnic disparities in prevalence, treatment and control of hypertension - United States, 1999-2002. MMWR Morbid Mortal Wkly Rep. 2005;54:7-9.
6. Okonofua EC, Cutler NE, Lackland DT, Egan BM. Ethnic differences in older Americans: awareness, knowledge and beliefs about hypertension. Am J Hypertens. 2005;18:972-979.
7. Aranda JM, Vazquez R. Awareness of hypertension and diabetes in the Hispanic community. Clin Cornerstone. 2004;6:7-15.
8. Betancourt JR, Carrillo JE, Green AR, Maina A. Barriers to health promotion and disease prevention in the Latino population. Clin Cornerstone. 2004;6:16-29.
9. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT, Cushman WC, Grimm RH, LaRosa J, Whelton PK, Perry HM, Alderman MH, Ford CE, Oparil S, Francis C, Proschan M, Pressel S, Black HR, Hawkins CM. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens. 1996;9:342-360.
10. Grimm RH, Margolis KL, Papademetriou V, Cushman WC, Ford CE, Bettencourt J, Alderman MH, Basile JN, Black HR, DeQuattro V, Eckfefldt J, Hawkins CM, Proschan M. Baseline characteristics of participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2001;37:19-27.
11. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens. 2002;4:393-404.
12. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2000;283:1967-1975.
13. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
14. U.S. Census Bureau. USA QuickFacts from the Census Bureau. Available at: http://quickfacts.census.gov/qfd/states/00000.html. Accessed October 23, 2006.
15. Borrell LN. Self-reported hypertension and race among Hispanics in the National Health Interview Survey. Ethn Dis. 2006;16:71-77.
16. Cooper-DeHoff RM, Aranda JM Jr, Gaxiola E, Cangiano JL, Garcia-Barreto D, Conti CR, Hewkin A, Pepine CJ. Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients - findings from the International Verapamil SR/Trandolapril Study (INVEST). Am Heart J. 2006;151:1072-1079.
17. Lloyd-Jones DM, Sutton-Tyrrell K, Patel AS, Matthews KA, Pasternak RC, Everson-Rose SA, Scuteri A, Chae CU. Ethnic variation in hypertension among premenopausal and perimenopausal women: study of women's health across the nation. Hypertension. 2005;46:689-695.
18. Pavlik VN, Hyman DJ, Vallbona C. Hypertension control in multi-ethnic primary care clinics. J Human Hypertens. 1996;10(suppl 3):S19-S23.
19. Haffner SM, Morales PA, Hazuda HP, Stern MP. Level of control of hypertension in Mexican Americans and non-Hispanic whites. Hypertension. 1993;21:83-88.
20. Satish S, Stroup-Benham CA, Espino DV, Markides KS, Goodwin JS. Undertreatment of hypertension in older Mexican Americans. J Am Geriatrics Soc. 1998;46:405-410.
21. Lin H, Bermudez OI, Falcon LM, Tucker KL. Hypertension among Hispanic elders of a Caribbean origin in Massachusetts. Ethnicity Dis. 2002;12:499-507.
22. Crespo CJ, Loria CM, Burt VL. Hypertension and other cardiovascular disease risk factors among Mexican Americans, Cuban Americans, and Puerto Ricans from the Hispanic Health and Nutrition Examination Survey. Pub Health Rep. 1996;111(suppl 2):7-10.
23. Centers for Disease Control and Prevention. Access to health-care and preventive services among Hispanics and non-Hispanics - United States, 2001-2002. MMWR Morbid Mortal Wkly Rep. 2004;53:937-941.
24. Corbie-Smith G, Flagg EW, Doyle JP, O'Brien MA. Influence of usual source of care on differences by race/ethnicity in receipt of preventive services. J Gen Intern Med. 2002;17:458-464.
25. Stewart SH, Silverstein MD. Racial and ethnic disparity in blood pressure and cholesterol measurement. J Gen Intern Med. 2002;17:405-411.
26. Shea S, Misra D, Ehrlich MH, Field L, Francis CK. Correlates of nonadherence to hypertension treatment in an inner-city minority population. Am J Pub Health. 1992;82:1607-1612.
27. Breisacher B, Limcango R, Gaskin D. Racial and ethnic disparities in prescription coverage and medication use. Health Care Financing Rev. 2003;25:63-76.
28. Sudano JJ, Baker DW. Antihypertensive medication use in Hispanic adults: a comparison with black adults and white adults. Med Care. 2001;39:575-587.
29. Raji MA, Kuo Y, Salazar JA, Satish S, Goodwin JS. Ethnic differences in antihypertensive medication use in the elderly. Ann Pharmacother. 2004;38:209-214.
30. Ayala C, Neff LJ, Croft JB, Keenan NL, Malarcher AM, Hyduk A, Bansil P, Mensah GA. Prevalence of self-reported high blood pressure awareness, advice received from health professionals, and actions taken to reduce high blood pressure among US adults - Healthstyles 2002. J Clin Hypertens. 2005;7:513-519.
31. Winkleby MA, Fortmann SP, Rockhill B. Health-related risk factors in a sample of Hispanics and whites matched on sociodemographic characteristics. Am J Epidemiol. 1993;137:1365-1375.
32. Kramer H, Han C, Post W, Goff D, Diez-Roux A, Cooper R, Jinagouda S, Shea S. Racial/ethnic differences in hypertension and hypertension treatment and control in the multi-ethnic study of atherosclerosis (MESA). Am J Hypertens. 2004;17:963-970.
33. Hicks LS, Fairchild DG, Horng MS, Orav EJ, Bates DW, Ayanian JZ. Determinants of JNC VI guideline adherence, intensity of drug therapy, and blood pressure control by race and ethnicity. Hypertension. 2004;44:429-434.
34. Jamerson K, DeQuattro V. The impact of ethnicity on response to antihypertensive therapy. Am J Med. 1996;101(suppl 3A):22S-32S.
35. Ofili EO, Ferdinand KC, Saunders E, Neutel JM, Bakris GL, Cushman WC, Sowers JR, Weber MA. Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy. J Natl Med Assn. 2006;98:618-626.
36. Nietert PJ, Wessell AM, Feifer C, Ornstein SM. Effect of terminal digit preference on blood pressure measurement and treatment in primary care practices. Am J Hypertens. 2006;19:147-152.
37. Graves JW, Bailey KR, Grossardt BR, Gullerud RE, Meverden RA, Grill DE, Sheps SG. The impact of observer and patient factors on the occurrence of digit preference for zero in blood pressure measurement in a hypertension specialty clinic: Evidence for the need of continued observation. Am J Hypertens. 2006;19:567-572.
38. Reid CM, Ryan P, Miles H, Willson K, Beilin LJ, Brown MA, Jennings GL, Johnston CI, Macdonald GJ, Marley JE, Mcneil JJ, Morgan TO, West MJ, Wing LMH. Who's really hypertensive? Quality control issues in the assessment of blood pressure for clinical trials. Blood Pressure. 2005;14:133-138.
39. Wingfield D, Cooke J, Thijs L, Staessen JA, Fletcher AE, Fagard R, Bulpitt CJ, on behalf of the Syst-Eur Investigators. Terminal-digit preference and single-number preference in the Syst-Eur trial: influence of quality control. Blood Press Monit. 2002;7:169-177.